Wexford Capital LP Cullinan Oncology, Inc. Transaction History
Wexford Capital LP
- $638 Million
- Q3 2025
A detailed history of Wexford Capital LP transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Wexford Capital LP holds 5,317 shares of CGEM stock, worth $45,460. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,317
Previous 18,726
71.61%
Holding current value
$45,460
Previous $141,000
78.01%
% of portfolio
0.0%
Previous 0.05%
Shares
2 transactions
Others Institutions Holding CGEM
# of Institutions
148Shares Held
65.1MCall Options Held
10.7KPut Options Held
14.4K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$65.4 Million8.21% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.77MShares$49.3 Million6.64% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$49.2 Million1.84% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$30.4 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$29.2 Million15.23% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $390M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...